Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q7Z444
UPID:
RASE_HUMAN
Alternative names:
Embryonic stem cell-expressed Ras
Alternative UPACC:
Q7Z444
Background:
GTPase ERas, also known as Embryonic stem cell-expressed Ras, is pivotal in cellular processes, binding GDP/GTP with intrinsic GTPase activity. Its role is crucial in maintaining the tumor-like growth characteristics of embryonic stem cells, suggesting a significant function in cellular proliferation and differentiation.
Therapeutic significance:
Understanding the role of GTPase ERas could open doors to potential therapeutic strategies. Its involvement in the regulation of embryonic stem cell growth highlights its potential as a target for innovative treatments in regenerative medicine and cancer therapy.